Study finds GLP-1 weight rebound risk

The Baltimore Sun reported on May 20 that new research adds to evidence that weight lost on GLP-1 drugs often returns after treatment ends. The report pointed to a broader clinical question that has followed the rise of semaglutide and tirzepatide: what happens after patients stop taking them. Recent studies have found weight regain is common after discontinuation, though newer real-world data suggest outcomes vary depending on whether patients restart treatment or move to other therapies. Researchers have also reported that some of the metabolic gains seen during treatment can fade after the drugs are stopped. ### Which research is driving the rebound concern? A BMJ systematic review and meta-analysis published on January 7 examined 37 studies covering 9,341 adults who stopped medication for weight management. The review found that people regained an average of 0.4 kilograms, or about 0.9 pounds, a month after stopping treatment, according to the BMJ and the University of Oxford, which highlighted the findings in a January 8 release. (bmj.com) The Oxford team said regain on newer medicines such as semaglutide and tirzepatide averaged 0.8 kilograms a month, or about 1.8 pounds, with projections indicating a return to baseline weight in roughly 1.5 years, though data beyond 12 months remained limited. Dr. Sam West, a postdoctoral researcher at Oxford’s Nuffield Department of Primary Care Health Sciences and the lead author, said the pattern reflects obesity as “a chronic, relapsing condition,” not a failure of the drugs. (bmj.com) ### What else did the review say changes after treatment stops? The BMJ review said cardiometabolic markers including HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides improved during treatment but were projected to return to baseline within about 1.4 years after medicines stopped. The analysis compared drug discontinuation with ending behavioral weight-loss programs and found regain after weight-management medication was faster by about 0.3 kilograms a month. (ox.ac.uk) A Lancet eClinicalMedicine analysis also examined “metabolic rebound” after GLP-1 receptor agonist discontinuation, underscoring that the issue extends beyond body weight alone. The Baltimore Sun’s framing around metabolic effects and the need for follow-up care is consistent with that line of research, though the details in the BMJ review are the clearest quantified findings available from primary reporting surfaced here. (ox.ac.uk) ### Do all patients regain the weight? Cleveland Clinic said on March 12 that its analysis of 7,938 adults found a more mixed real-world picture. The health system said 45% of patients in its obesity group kept losing weight or stayed the same one year after discontinuing semaglutide or tirzepatide, while 55% gained weight. (thelancet.com) Hamlet Gasoyan, a Cleveland Clinic researcher who led that study, said many patients restarted the original medication or switched to another obesity treatment, which may help explain why average regain in practice looked smaller than in randomized trials. In that study, patients treated for obesity lost an average of 8.4% of body weight before discontinuation and regained an average of 0.5% one year later. (newsroom.clevelandclinic.org) ### Why do researchers say the results differ between trials and practice? Cleveland Clinic said treatment pathways after discontinuation matter. The system reported that patients often did not simply stop therapy and remain untreated; many restarted a GLP-1 drug, moved to another obesity treatment, or used lifestyle interventions. (newsroom.clevelandclinic.org) The BMJ review, by contrast, pooled evidence across many studies to estimate the average trajectory after stopping weight-management medication. That makes the two findings complementary rather than directly contradictory: one describes aggregate rebound across trials and studies, while the other tracks what happened in a large clinical population where re-treatment and follow-up were common. (newsroom.clevelandclinic.org) ### Are there any proposed ways to limit rebound? The BMJ reported on May 13 that a small Nature Medicine study tested switching patients from injectable GLP-1 drugs to Eli Lilly’s daily oral drug orforglipron. In that 376-person study, patients who switched maintained 75% to 79% of their earlier weight reduction after a year, compared with 38% to 49% for placebo groups, though the report said the results need confirmation in larger trials. (bmj.com) The next evidence to watch is likely to come from longer-term discontinuation studies and follow-up trials designed around maintenance treatment. The BMJ meta-analysis, Cleveland Clinic’s one-year data and newer maintenance studies are now the main reference points for clinicians tracking what happens after GLP-1 treatment ends. (bmj.com 1) (bmj.com 2)